Tìm theo
N,N-dimethylarginine
Các tên gọi khác (11 ) :
  • Asymmetric dimethylarginine
  • Dimethyl-l-arginine
  • Guanidino-n,n-dimethylarginine
  • N(5)-((Dimethylamino)iminomethyl)-L-ornithine
  • N(5)-[(dimethylamino)(imino)methyl]-L-ornithine
  • N(g)-dimethylarginine
  • N(g),N(g)-dimethyl-l-arginine
  • N(g),N(g)-dimethylarginine
  • N(G1),N(G1)-Dimethylarginine
  • N(omega),N(omega)-dimethyl-l-arginine
  • NG,NG-dimethyl-l-arginine
enzyme inhibitors
Thuốc Gốc
Small Molecule
CAS: 102783-24-4
CTHH: C8H18N4O2
PTK: 202.2541
Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health. [Wikipedia]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C8H18N4O2
Phân tử khối
202.2541
Monoisotopic mass
202.14297584
InChI
InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1
InChI Key
InChIKey=YDGMGEXADBMOMJ-LURJTMIESA-N
IUPAC Name
(2S)-2-amino-5-[(E)-[amino(dimethylamino)methylidene]amino]pentanoic acid
Traditional IUPAC Name
N,N-dimethylarginine
SMILES
N[C@@H](CCC\N=C(/N)N(C)C)C(O)=O
Độ hòa tan
6.77e+00 g/l
logP
-2.7
logS
-1.5
pKa (strongest acidic)
2.54
pKa (Strongest Basic)
12.34
PSA
104.94 Å2
Refractivity
53.7 m3·mol-1
Polarizability
22.19 Å3
Rotatable Bond Count
5
H Bond Acceptor Count
6
H Bond Donor Count
3
Physiological Charge
1
Number of Rings
0
Bioavailability
1
Rule of Five
true
Dược Lực Học : Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is formed by methylation of arginine residues in proteins and released after proteolysis. In this reaction, S-adenosylmethionine is methyldonor and S-adenosylhomocysteine the demethylated product. ADMA and homocysteine are thus biochemically linked. Both plasma homocysteine and ADMA concentrations are increased in patients with renal dysfunction, probably as a result of an impairment in their metabolic, but not urinary, clearance. Hyperhomocysteinemia has been associated with an increased risk of cardiovascular disease in end-stage renal disease, especially in patients without malnutrition and inflammation. Also, plasma ADMA levels have been associated with cardiovascular disease in renal failure patients. Both homocysteine and ADMA are thought to mediate their adverse vascular effects by impairing endothelial, nitric oxide-dependent function resulting in decreased vasodilatation, increased smooth muscle cell proliferation, platelet dysfunction and increased monocyte adhesion.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01686
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=123831
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508091
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C03626
ChemSpider
http://www.chemspider.com/Chemical-Structure.487.html
Wikipedia
http://en.wikipedia.org/wiki/Asymmetric_dimethylarginine
... loading
... loading